First Gene Editing Cure Shows 87% Attack Reduction in Trial

Imagine living with the constant fear that your throat could suddenly swell shut, or that unpredictable attacks could strike anywhere on your body at any time. That's the reality for people with hereditary angioedema, a rare genetic disorder that causes severe, recurring swelling episodes. Now, scientists have developed what could become the first one-time cure.

Intellia Therapeutics just announced that their experimental CRISPR treatment, lonvo-z, met every goal in a global Phase 3 trial involving 80 patients. The results represent the first successful Phase 3 trial for any in vivo gene editing therapy, meaning the treatment edits genes directly inside the body rather than in a lab.

The numbers tell a stunning story. Patients who received a single infusion experienced 87% fewer attacks over six months compared to those who got a placebo. Even more remarkable, 62% of treated patients were completely attack-free and didn't need any other medication during that period, compared to just 11% in the placebo group.

The treatment works by permanently turning off a gene called KLKB1, which stops the overproduction of bradykinin, the chemical that triggers dangerous swelling. The one-time infusion takes place in an outpatient setting, and as of the data cutoff in February 2026, every patient who received the treatment remained free from needing daily medication.

Safety data looked encouraging too. The most common side effects were mild or moderate infusion reactions, headaches, and fatigue. No serious adverse events occurred in patients who received lonvo-z.

Why This Inspires

For decades, patients with hereditary angioedema have juggled the anxiety of unpredictable attacks with the burden of chronic medication. Dr. Aleena Banerji, who helped lead the trial at Massachusetts General Hospital, explained that even with available treatments, many patients still struggle with breakthrough attacks and daily therapy challenges.

This breakthrough represents more than medical progress. It's the culmination of years of patients volunteering for clinical trials, advancing science that could transform their lives and others facing similar conditions. Intellia has already begun the FDA approval process and expects to launch in the United States by mid-2027 if approved.

The success opens doors beyond this single disease. Proving that in vivo gene editing can work safely and effectively in a Phase 3 trial validates the entire approach, potentially accelerating treatments for countless other genetic conditions.

Within two years, people born with this painful disorder might have access to a genuine cure delivered in a single appointment.